Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers - Seitz, Lisa; Jin, Lixia; Leleti, Manmohan; Ashok, Devika; Jeffrey, Jenna; Rieger, Aimee; Tiessen, Renger G.; Arold, Gerhard; Tan, Joanne B. L.; Powers, Jay P.; Walters, Matthew J.; Karakunnel, Joyson (Investigational new drugs, 2019)
Keywords: Absorption; Adenosine; Administration, Oral; Adolescent; Adult; Antitumor activity; Cancer; CD8-Positive T-Lymphocytes - drug effects; CD8-Positive T-Lymphocytes - metabolism; Cyclic AMP; Cyclic AMP response element-binding protein; Cyclic AMP Response Element-Binding Protein - metabolism; Double-Blind Method; Female; Food-Drug Interactions; Healthy Volunteers; Humans; Immune response; Immune system; Immunotherapy; Inhibition; Iron; Male; Medicine; Medicine & Public Health; Middle Aged; Oncology; Parameter identification; Parameter sensitivity; Pharmacodynamics; Pharmacokinetics; Pharmacology; Pharmacology/Toxicology; Phase I Studies; Phosphorylation; Plasma levels; Proteins; Purinergic P1 Receptor Antagonists - administration & dosage; Purinergic P1 Receptor Antagonists - blood; Purinergic P1 Receptor Antagonists - pharmacokinetics; Randomization; Receptors; Safety; Studies; Young Adult; Adenosine signaling; Oncology; Adenosine receptor antagonist; Healthy volunteers; AB928; Immunotherapy